Testosterone Replacement in Male Cancer Survivors with Fatigue and Low Testosterone

Last updated: March 6, 2025
Sponsor: Seattle Institute for Biomedical and Clinical Research
Overall Status: Active - Recruiting

Phase

2

Condition

Pain (Pediatric)

Hypogonadism

Treatment

Testosterone Undecanoate 750 MG/3 ML Intramuscular Solution [AVEED]

placebo

Clinical Study ID

NCT04049331
01751
  • Ages 18-54
  • Male

Study Summary

The overall goal of this study is to evaluate the effect of a testosterone drug called Depo-Testosterone (or 'testosterone cypionate'), an FDA-approved drug for improving fatigue, sexual function, quality of life, body composition, muscle strength, and physical activity in young cancer survivors who report fatigue and have low testosterone. Main hypothesis is that Testosterone administration in young male cancer survivors who are in remission for at least 1 year, report cancer-related fatigue and have symptomatic testosterone deficiency will be associated with greater improvements in fatigue scores compared with placebo.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Cancer survivors who have received chemotherapy and/or radiation therapy for theircancer and are now in remission for at least one year

  • Non-hormone-dependent cancer, including most solid tumors, lymphomas and leukemias

  • Age: 18-54 years

  • Serum testosterone, measured by mass spectrometry (gold standard method), of <348ng/dl and/or free testosterone <70 pg/ml. The lower limits of the normal range fortotal testosterone in healthy young men (age 19-40 years), is 348 ng/dL and thelower limits of free testosterone is <70 pg/ml in the Framingham Heart Studysample97. Therefore, young symptomatic men with total testosterone <348 ng/dl couldbe considered testosterone deficient. As sex hormone binding globulin levels may beelevated in some men with cancer (resulting in elevation in total testosteronelevel), some of these symptomatic men may still be hypogonadal despite having totaltestosterone above this cut-off limit. However; their free testosterone levels maystill be below the lower limit of normal. Thus, we will also include men with freetestosterone <70 pg/mL.

  • Self-reported fatigue. We have selected these symptoms because they are commonlyreported in male cancer survivors. Fatigue will be defined as a score on FunctionalAssessment of Chronic Illness Therapy-Fatigue (FACIT-F) subscale of <40, which bestdivides cancer patients from the general population with 84% accuracy, and was usedas the cut-off for the NIA-funded 50-million-dollar testosterone trial (TheT-Trial).

  • Ability and willingness to provide informed consent.

Exclusion

Exclusion Criteria:

  • Men with hormone-dependent cancers (breast, prostate or adenocarcinoma of unknownorigin)

  • Men with brain cancer (potential cognitive impairment)

  • Use of anabolic agents (testosterone, dehydroepiandrosterone, growth hormone) withinthe past 6 months

  • Appetite stimulating agents e.g. megestrol acetate within the past 6 months

  • Systemic glucocorticoids e.g. prednisone 20 mg daily or equivalent doses of otherglucocorticoids for more than two weeks in the past 6 months

  • Baseline hematocrit >48%

  • PSA >4 ng/ml in Caucasians; >3 ng/ml in African-Americans

  • Men with 1st order relatives with a history of prostate cancer

  • Uncontrolled congestive heart failure

  • Severe untreated sleep apnea

  • Myocardial infarction, acute coronary syndrome, revascularization surgery, or strokewithin 3 months o Previous stroke with residual cognitive or functional deficits; Mini-Mental StateExamination score <24

  • Serum creatinine >2.5 mg/dL; ALT 3x upper limit of normal

  • Poorly controlled diabetes as defined by hemoglobin A1c >8.5%; Body mass index (BMI) >45 kg/m2

  • Untreated unipolar depression (treated depression with medications or counselingwill be allowed

  • Bipolar disorder or schizophrenia

Study Design

Total Participants: 240
Treatment Group(s): 2
Primary Treatment: Testosterone Undecanoate 750 MG/3 ML Intramuscular Solution [AVEED]
Phase: 2
Study Start date:
March 22, 2021
Estimated Completion Date:
January 30, 2027

Study Description

The overall goal of this proposal is to evaluate the efficacy of testosterone replacement therapy in improving fatigue and other outcomes such as sexual function, quality of life, body composition, muscle strength and physical activity in a double-blind, randomized, placebo-controlled trial in young cancer survivors who report fatigue and have testosterone deficiency.

Fatigue is one of the most prevalent and debilitating symptoms in men with cancer affecting 70-100% of patients irrespective of their age. Cancer-related fatigue is experienced by patients not only during active cancer treatment, but is also highly prevalent in cancer survivors who exhibit persistent fatigue months to years after the end of their treatment with the highest prevalence being in recipients of chemotherapy and/or radiation therapy.

In addition to fatigue, sexual dysfunction is also highly prevalent in male cancer survivors. Male cancer survivors also have increased fat mass and decreased lean body mass, a phenotype that predisposes them to reduced muscle strength. This phenotype of fatigue, sexual dysfunction and adverse body composition is commonly encountered in non-cancer patient populations with testosterone deficiency, a condition which is also highly prevalent (50-90%) in cancer survivors. Pivotal trials of testosterone replacement therapy in non-cancer patient populations have shown an improvement in fatigue, sexual function and body composition in men randomized to testosterone compared with placebo. However, the efficacy of testosterone replacement therapy on cancer-related fatigue has not been studied.

Connect with a study center

  • Brigham and Women's Hospital

    Boston, Massachusetts 02115
    United States

    Active - Recruiting

  • Veterans Affairs Puget Sound Health Care System

    Seattle, Washington 98108
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.